Mary L. Disis

RT @uwmnewsroom: 5 immune response markers might predict #COVID19 patient outcomes & possibly become useful in candidate vaccine assessment…

RT @JackWestMD: In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCL…

RT @0131Liu: Thanks for my nicest colleagues! I am the best, because all of you! @UWCancerVaccine

Laura is an amazing scientist!

UW Cancer Vaccine Institute @UWCancerVaccine

CVI’s Dr. Laura Riolobos is making a #vaccine for #liposarcoma, to help her friend & others with this rare #cancer. Read more: https://t.co/QQv9f3U6vu @UWMedicine #SarcomaAwareness #CureSarcoma #Sarcoma #Research https://t.co/gEqeEaK5gr

Pembrolizumab After Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer https://t.co/9AqQsD6lmj New at @JAMA Onc-ablation of oligometastatic NSCLC followed by immune checkpoint: OS at 12 mo-90%. Novel and promising application of immune checkpoint inhibition.

Regulatory roles of IL-10–producing human follicular T cells https://t.co/k5EP4F364j

I'm a fan of testing early. Immune therapy more be more effective with less bulky disease.

Tom Jayram @TomJayram

Fascinating. Test early or late in the disease course? Seems like later could pick up more candidates for IO

RT @guptaarjun90: Patient page on #CIPN (Chemo Induced Peripheral Neuropathy), in @JAMAOnc w/ @TimothyJBrownMD @ramsedhom #QOL matters. Ca…

Thank you UW CVI #ImmunoOnc19 @UWCancerVaccine

Ravi A Madan M.D. @Dr_RaviMadan

Just a reminder that you can’t top @thenci ‘s @gulleyj1 for #immunotherapy on Twitter 😉. Thank you also @DrChoueiri @DrNDisis @asco @sitc @PGrivasMDPhD @xiaoweimd @CMAnnunziata @phase1oncomd et al for a great #ImmunoOnc19.

VERY IMPORTANT COMMENT!!! #ImmunoOnc19 @UWCancerVaccine

A.n.n. @fireflyann

if presenters include NCT trial number 1) attendees can look at some of the perameters of trial (e.g. dosing) 2) clinicians can find out that this presentation of findings exist 3) if there is a related trial (or an open arm), patients can find out more about trial. #ImmunoOnc19

Dr. Kandalaft points out that there are many types of antigens that can be used for vaccination, neo antigens of all types- not just point mutations. Target epigenetic changes, phospho Ag...etc. #ImmunoOnc19 @UWCancerVaccine https://t.co/kuiVvRYziQ

Dr. Palucka highlights the importance of DC in mediating response to ICI. Recent Immunity paper implicated IFN-g and IL-12 in T cell DC cross-talk. https://t.co/GMz0gUVuF4 #ImmunoOnc19 @UWCancerVaccine

Dendritic cells are the most important antigen presenting cells for stimulating T-cell responses to cancer. Nobel Prize winning tumor immunologist Dr. Ralph Steinman was honored for his work in this area. #ImmunoOnc19

Dr. Palucka highlights the issues associated with mutated antigen vaccines; the mutations have to be presented enodogenously in the patients MHC. Most are not. #Immunotherapy #immunoonc19 @UWCancerVaccine https://t.co/lrnfIS28Mt

Sounds exciting for endometrial cancer! #ImmunoOnc19

Surely there must be more data supporting a Phase III than just these 20 patients....!!!!#ImmunoOnc19

Allison Betof Warner, MD, PhD @DrBetofMDPhD

Phase II arm of lenvatinib + pembro in urothelial ca. n=20 pts. ORR 25% (5 objective responses + 7 decreased tumor size that didn't meet criteria). But, significant treatment related AE's frequent, including a fatal GI hemorrhage. Phase 3 coming- what do you think? #ImmunoOnc19 https://t.co/aubYYQirCh

Many talks are associating PD-L1 tumor expression with clinical outcome- yet don't tell us definition of PD-L1 positivity. Is it 50%, 5%, 1%? On tumor? On immune "hot-spots"? on APC? Hard to figure out the utility of association. #ImmunoOnc19 @UWCancerVaccine